|
gptkbp:instance_of
|
gptkb:Company
|
|
gptkbp:bfsLayer
|
5
|
|
gptkbp:bfsParent
|
gptkb:Allergan's_aesthetics_portfolio
gptkb:ALX-0699
|
|
gptkbp:acquired
|
gptkb:Abb_Vie
|
|
gptkbp:acquisition
|
gptkb:2019
Allergan Inc.
|
|
gptkbp:ceo
|
gptkb:David_M._Pyott
|
|
gptkbp:employees
|
approximately 18,000
|
|
gptkbp:focus
|
neuroscience
dermatology
women's health
ophthalmology
urology
gastroenterology
eye care
medical aesthetics
|
|
gptkbp:founded
|
gptkb:1983
|
|
gptkbp:founder
|
J. M. Allergan
|
|
gptkbp:headquarters
|
gptkb:Dublin
gptkb:Dublin,_Ireland
gptkb:Ireland
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Allergan plc
|
|
gptkbp:industry
|
gptkb:drug
|
|
gptkbp:market
|
global
|
|
gptkbp:notable_products
|
gptkb:Breztri_Aerosphere
gptkb:Cool_Sculpting
gptkb:Kybella
gptkb:Latisse
gptkb:Ozurdex
gptkb:Vraylar
gptkb:Rhinocort
Cynapsus Therapeutics
Aczone
Aesthetics portfolio
Allergan's pipeline
Alyacen
BOTOX Cosmetic
Bimatoprost
Daxibotulinumtoxin A
Dermatology portfolio
Eye care portfolio
Gastroenterology portfolio
Namzaric
Neuroscience portfolio
Urology portfolio
Viberzi
Women's health portfolio
|
|
gptkbp:parent_company
|
gptkb:Abb_Vie_Inc.
|
|
gptkbp:products
|
gptkb:Botox
gptkb:Juvederm
gptkb:Restasis
|
|
gptkbp:revenue
|
$16.1 billion (2019)
|
|
gptkbp:subsidiary
|
gptkb:Allergan_Medical
gptkb:Allergan_Aesthetics
|
|
gptkbp:symbol
|
gptkb:AGN
|
|
gptkbp:type
|
gptkb:Company
|
|
gptkbp:website
|
www.allergan.com
|